scholarly journals Left ventricular dilatation is associated with increased risk of congestive heart failure: The Framingham heart study

1996 ◽  
Vol 27 (2) ◽  
pp. 89
Author(s):  
Ramachandran S. Vasan ◽  
Martin G. Larson ◽  
Jane C. Evans ◽  
Emelia J. Benjamin ◽  
Daniel Levy
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Framingham Heart Study ◽  
Left Ventricular ◽  
Ventricular Dilatation ◽  
Left Ventricular Dilatation ◽  
Heart Study ◽  
Increased Risk

Homocysteine and heart failure: a review of investigations from the Framingham Heart Study

2005 ◽  
Vol 43 (10) ◽  
Author(s):  
Johan Sundström ◽  
Ramachandran S. Vasan
Keyword(s):  
Heart Failure ◽  
Framingham Heart Study ◽  
Randomized Clinical Trials ◽  
Left Ventricular ◽  
Plasma Homocysteine ◽  
Community Based ◽  
Failure Risk ◽  
Heart Study ◽  
Increased Risk ◽  
Lv Mass

AbstractHigh plasma homocysteine levels are associated with a moderately increased risk of cardiovascular disease, particularly of atherosclerotic events. We review the association of plasma homocysteine with heart failure, with a specific focus on a series of previously published investigations from the community-based Framingham Heart Study that evaluated the relations of plasma homocysteine levels with overt heart failure, and with its key antecedents, echocardiographic left ventricular (LV) mass and hypertension. In the Framingham sample, higher plasma homocysteine levels were associated with increased risk of new-onset heart failure in both men and women, with a more continuous and graded relation being observed in women. A positive relation between homocysteine and LV mass was observed in women, but not in men; this may underlie the stronger relations of homocysteine to heart failure risk in women. Plasma homocysteine was not associated with hypertension incidence prospectively in either sex. The relations of increased homocysteine to heart failure (in both sexes) and to greater LV mass (in women) noted in the Framingham sample should be confirmed in other community-based samples. Secondary analyses of heart failure outcomes in ongoing randomized clinical trials may provide insights into whether lowering of plasma homocysteine levels is associated with a reduction in LV mass and/or a reduction of heart failure risk.

Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: The Framingham Heart Study

2002 ◽  
Vol 144 (4) ◽  
pp. 733-739 ◽  
Author(s):  
Craig R. Walsh ◽  
L.Adrienne Cupples ◽  
Daniel Levy ◽  
Douglas P. Kiel ◽  
Marian Hannan ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Framingham Heart Study ◽  
Abdominal Aortic ◽  
Heart Study ◽  
Increased Risk ◽  
Calcific Deposits

Left Ventricular Dilatation and the Risk of Congestive Heart Failure in People without Myocardial Infarction

1997 ◽  
Vol 336 (19) ◽  
pp. 1350-1355 ◽  
Author(s):  
Ramachandran S. Vasan ◽  
Martin G. Larson ◽  
Emelia J. Benjamin ◽  
Jane C. Evans ◽  
Daniel Levy
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Congestive Heart Failure ◽  
Left Ventricular ◽  
Ventricular Dilatation ◽  
Left Ventricular Dilatation

Atrial functional mitral regurgitation: mechanisms and surgical implications

2020 ◽  
Vol 28 (7) ◽  
pp. 421-426
Author(s):  
Yiting Fan ◽  
Song Wan ◽  
Randolph Hung-Leung Wong ◽  
Alex Pui-Wai Lee
Keyword(s):  
Mitral Regurgitation ◽  
Left Ventricular ◽  
Ventricular Dilatation ◽  
Functional Mitral Regurgitation ◽  
Current Evidence ◽  
Disease Entity ◽  
Risk Of Death ◽  
Left Ventricular Dilatation ◽  
Annular Dilatation ◽  
Increased Risk

The term atrial functional mitral regurgitation refers to a newly recognized disease entity in which mitral regurgitation occurs secondary to left atrial disease, without left ventricular dilatation and intrinsic mitral valve disease, typically in the setting of long-standing atrial fibrillation. Recent evidence suggests that atrial functional mitral regurgitation is associated with increased risk of death and heart failure re-hospitalization. The etiology, pathophysiology, and mechanism of atrial functional mitral regurgitation is not completely understood but they should not be regarded as the same as for the conventional type of functional mitral regurgitation secondary to left ventricular dilatation and dysfunction. Mitral annular dilatation, atriogenic leaflet distortion, insufficient leaflet remodeling, and subtle left ventricular dysfunction may play a role in the pathogenesis of atrial functional mitral regurgitation. The therapeutic and surgical considerations of atrial functional mitral regurgitation are different from those of ventricular functional mitral regurgitation. In this review, we assess current evidence regarding this new disease entity and propose a new surgical approach based on up-to-date understanding and experience of this condition.

Sign in / Sign up

Export Citation Format

Share Document